Brief: LAVA Therapeutics Announces Selection By Janssen Of Lead Gamma-Delta T-Cell Engager Bispecific Antibody

LAVA Therapeutics NV

01/06/2023 22:40

June 1 (Reuters) - LAVA Therapeutics NV  LVTX.O :
    * LAVA THERAPEUTICS ANNOUNCES SELECTION BY JANSSEN OF LEAD
GAMMA-DELTA T-CELL ENGAGER BISPECIFIC ANTIBODY TO MOVE TOWARD
CLINICAL DEVELOPMENT
    * LAVA THERAPEUTICS NV - ELIGIBLE TO RECEIVE POTENTIAL
DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONE PAYMENTS
AND TIERED ROYALTIES

Source text for Eikon:  ID:nGNX6BCSG8 
Further company coverage:  LVTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))